Gapping up
In reaction to strong earnings/guidance:
- LAKE +45.4%, AMC +13%, FIVE +10.4%, ITI +6.4%, AGX +4.4%, CVS +0.9% (guidance)
Other news:
- DUO +48.5% (states that in light of the increases in the price and trading volume, its policy is not to comment on unusual market activity or speculative matters)
- APT +16.4% (up in sympathy on strong quarter from LAKE)
- BVXV +14.7% (announced the completion of the clinical study report (CSR) of a Phase 2 clinical trial of the Company's M-001 universal influenza vaccine candidate)
- RADA +10.6% (announced the receipt of over $25 million in new orders during the months of April and May 2020, a record for a two month time period)
- APAM +7.9% (reports assets under management)
- TSLA +5.5% (Elon Musk says it is time to bring Tesla Semi to volume production; most of production will occur outside of California) GMAB +5% (Genmab and Abbvie (ABBV) enter collaboration to jointly develop and commercialize three of Genmab's oncology products; GMAB raises FY20 guidance)
- RDHL +3.5% (submits Clinical Trial Application with the Ministry of Health of the Russian Federation for a Phase 2/3 clinical study evaluating opaganib in patients hospitalized with severe SARS-CoV-2 infection and pneumonia)
- FULC +3.5% (plans to evaluate losmapimod as a potential treatment for patients with COVID-19)
- APTV +1.6% (prices offerings of 13,173,495 ordinary shares at $75.91 per share and 10,000,000 5.50% Series A Mandatory Convertible Preferred Shares)
- AB +1.5% (reports assets under management)
- IVZ +1.5% (reports assets under management)
- QDEL +1.4% (receives amended Emergency Use Authorization from the FDA)
Analyst comments:
- ETSY +4.1% (upgraded to Buy from Hold at Jefferies)
- MRTN +1.8% (upgraded to Buy from Hold at Loop Capital)
- CEM +1.2% (upgraded to Neutral from Underperform at BofA/Merrill)